Meeting
2014 ASCO Annual Meeting
Genetic variants of TCF7L2 and AXIN2 predict gender and tumor location-dependent clinical outcome in FIRE-3 trial: A validation study.
Authors
Yan Ning
USC Norris Comprehensive Cancer Center, Los Angeles, CA
Yan Ning , Sebastian Stintzing , Volker Heinemann , Wu Zhang , Dongyun Yang , Yu Sunakawa , Stefan Stremitzer , Ana Sebio , Shinichi Yamauchi , Satoshi Matsusaka , Rita Elkhoueiry , Afsaneh Barzi , Anthony B. El-Khoueiry , Heinz-Josef Lenz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3602)
DOI
10.1200/jco.2014.32.15_suppl.3602
Abstract #
3602
Poster Bd #
65
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Use of genetic variants in wnt signaling pathway to predict gender and tumor location dependent survival in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI and bevacizumab (BEV).
First Author: Yan Ning
Poster
2018 Gastrointestinal Cancers Symposium
Genetic variants in methylation and demethylation pathways to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/Bev: Data from TRIBE and FIRE-3 trials.
First Author: Alberto Puccini
Poster
2016 ASCO Annual Meeting
Genetic variants of R-spondin genes to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and bevacizumab (FOLFIRI/BEV) in FIRE-3 cohort.
First Author: Yan Ning
Poster
2015 ASCO Annual Meeting
Genetic variant of TWEAK to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and Bevacizumab (FOLFIRI/BEV) in FIRE-3 and TRIBE cohorts.
First Author: Anish Parekh